Nature Communications (Dec 2017)
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
- Daniel B. Lipka,
- Tania Witte,
- Reka Toth,
- Jing Yang,
- Manuel Wiesenfarth,
- Peter Nöllke,
- Alexandra Fischer,
- David Brocks,
- Zuguang Gu,
- Jeongbin Park,
- Brigitte Strahm,
- Marcin Wlodarski,
- Ayami Yoshimi,
- Rainer Claus,
- Michael Lübbert,
- Hauke Busch,
- Melanie Boerries,
- Mark Hartmann,
- Maximilian Schönung,
- Umut Kilik,
- Jens Langstein,
- Justyna A. Wierzbinska,
- Caroline Pabst,
- Swati Garg,
- Albert Catalá,
- Barbara De Moerloose,
- Michael Dworzak,
- Henrik Hasle,
- Franco Locatelli,
- Riccardo Masetti,
- Markus Schmugge,
- Owen Smith,
- Jan Stary,
- Marek Ussowicz,
- Marry M. van den Heuvel-Eibrink,
- Yassen Assenov,
- Matthias Schlesner,
- Charlotte Niemeyer,
- Christian Flotho,
- Christoph Plass
Affiliations
- Daniel B. Lipka
- Regulation of Cellular Differentiation Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Tania Witte
- Regulation of Cellular Differentiation Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Reka Toth
- Computational Epigenomics Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Jing Yang
- Division of Theoretical Bioinformatics (B080), German Cancer Research Center (DKFZ), INF 280
- Manuel Wiesenfarth
- Division of Biostatistics, German Cancer Research Center (DKFZ), INF 280
- Peter Nöllke
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine Medical Center, Faculty of Medicine, University of Freiburg
- Alexandra Fischer
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine Medical Center, Faculty of Medicine, University of Freiburg
- David Brocks
- Cancer Epigenetics Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Zuguang Gu
- Division of Theoretical Bioinformatics (B080), German Cancer Research Center (DKFZ), INF 280
- Jeongbin Park
- Division of Theoretical Bioinformatics (B080), German Cancer Research Center (DKFZ), INF 280
- Brigitte Strahm
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine Medical Center, Faculty of Medicine, University of Freiburg
- Marcin Wlodarski
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine Medical Center, Faculty of Medicine, University of Freiburg
- Ayami Yoshimi
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine Medical Center, Faculty of Medicine, University of Freiburg
- Rainer Claus
- Division of Hematology, Oncology and Stem Cell Transplantation, University Medical Center
- Michael Lübbert
- Division of Hematology, Oncology and Stem Cell Transplantation, University Medical Center
- Hauke Busch
- Institute of Molecular Medicine and Cell Research, University of Freiburg
- Melanie Boerries
- Institute of Molecular Medicine and Cell Research, University of Freiburg
- Mark Hartmann
- Regulation of Cellular Differentiation Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Maximilian Schönung
- Regulation of Cellular Differentiation Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Umut Kilik
- Regulation of Cellular Differentiation Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Jens Langstein
- Regulation of Cellular Differentiation Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Justyna A. Wierzbinska
- Regulation of Cellular Differentiation Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Caroline Pabst
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital
- Swati Garg
- Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital
- Albert Catalá
- Department of Hematology and Oncology, Hospital Sant Joan de Déu
- Barbara De Moerloose
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital
- Michael Dworzak
- St. Anna Children’s Hospital and Children’s Cancer Research Institute, Medical University of Vienna
- Henrik Hasle
- Department of Pediatrics, Aarhus University Hospital Skejby
- Franco Locatelli
- Department of Pediatric Hematology and Oncology, Bambino Gesú Children’s Hospital, University of Pavia
- Riccardo Masetti
- Department of Pediatric Oncology and Hematology, University of Bologna
- Markus Schmugge
- Department of Hematology and Oncology, University Children’s Hospital
- Owen Smith
- Department of Paediatric Oncology and Haematology, Our Lady’s Children’s Hospital Crumlin
- Jan Stary
- Department of Pediatric Hematology and Oncology, Charles University and University Hospital Motol
- Marek Ussowicz
- Department of Pediatric Hematology, Oncology and BMT, Wroclaw Medical University
- Marry M. van den Heuvel-Eibrink
- Princess Maxima Center for Pediatric Oncology
- Yassen Assenov
- Computational Epigenomics Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- Matthias Schlesner
- Division of Theoretical Bioinformatics (B080), German Cancer Research Center (DKFZ), INF 280
- Charlotte Niemeyer
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine Medical Center, Faculty of Medicine, University of Freiburg
- Christian Flotho
- Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine Medical Center, Faculty of Medicine, University of Freiburg
- Christoph Plass
- Cancer Epigenetics Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), INF 280
- DOI
- https://doi.org/10.1038/s41467-017-02177-w
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Juvenile myelomonocytic leukemia (JMML) is an aggressive disease with limited options for treatment. Here, the authors analyse the DNA methylome and mutational profile of JMML to define three subgroups with unique molecular and clinical characteristics.
